The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 5, 2006, Pages 945-949

  Helldén, Anders ^a   Lycke, Jan ^b   Vander, Tatiana ^c   Svensson, Jan Olof ^a   Odar Cederlöf, Ingegerd ^a   Ståhle, Lars ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

9 carboxymethoxymethylguanine; Neurotoxicity; Renal failure; Serious adverse reactions

Indexed keywords

9 CARBOXYMETHOXYMETHYLGUANINE; ACICLOVIR; DRUG METABOLITE; UNCLASSIFIED DRUG; VALACICLOVIR;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID EXAMINATION; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; HERPES SIMPLEX ENCEPHALITIS; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROTOXICITY; RECURRENT DISEASE; RETROSPECTIVE STUDY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SYMPTOMATOLOGY;

ACYCLOVIR; ANTIVIRAL AGENTS; GUANINE; HUMANS; MENTAL DISORDERS; NEUROTOXICITY SYNDROMES; RETROSPECTIVE STUDIES; VALINE;

EID: 33645826251     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl067     Document Type: Article

References (19)

1. Vartian C, Shlaes D. Intravenous acyclovir and neurologic effects. Ann Intern Med 1983; 99: 568.
2. Tilson H. Monitoring the safety of antivirals. Am J Med 1988; 85 Suppl 2A: 116-22.
3. Linssen-Schuurmans CD, van Kan EJ, Feith GW et al. Neurotoxicity caused by valacyclovir in a patient on hemodialysis. Ther Drug Monit 1998; 30: 385-6.
4. Peyriere H, Branger B, Bengler C et al. Toxicite neurologique induite par le Zelitrex (valaciclovir) chez trois patients insuffisants renaux. Surdosage lie a l'amelioration de la biodisponibilite du produit? Rev Med Interne 2000; 28: 297-303.
5. Wade J, Meyers J. Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation. Ann Intern Med 1983; 98: 921-5.
6. Itoh M, Hayakawa K. A girl with transient psychological disturbance caused by orally administered acyclovir - differentiation between acyclovir neurotoxicity and herpes simplex encephalitis. No To Hattatsu 1998; 78: 328-33.
7. Vander T, Medvedovsky M, Herishanu Y. Encephalopathy induced by oral acyclovir in a patient with normal renal function. J Infect 2003; 46: 286.
8. Feldman S, Rodman J, Gregory B. Excessive serum concentrations of acyclovir and neurotoxicity. J Infect Dis 1988; 157: 385-8.
9. de Knegt RJ, van der Pijl H, van Es LA. Acyclovir-associated encephalopathy, lack of relationship between acyclovir levels and symptoms. Nephrol Dial Transplant 1995; 10: 1775-7.
10. Haefeli WE, Schoenenberger RA, Weiss P et al. Acyclovir-induced neurotoxicity: Concentration-side effect relationship in acyclovir overdose. Am J Med 1993; 94: 212-5.
11. de Miranda P, Good SS. Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys. Drug Metab Dispos 1994; 22: 55-9.
12. de Miranda P, Burnette TC. Species differences in the metabolism and disposition of antiviral nucleoside analogues. Antiviral Chem Chemother 1992; 18: 1-8
13. de Miranda P, Good S, Laskin OL et al. Disposition of intravenous radioactive acyclovir. Clin Pharmacol Ther 1981; 30: 662-72
14. Helldén A, Odar-Cederlöf I, Diener P et al. High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: An observational study. Nephrol Dial Transplant 2003; 18: 1135-41.
15. Lycke J, Malmeström C, Ståhle L. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob Agents Chemother 2003; 47: 2438-41.
16. Bech E, Lycke J, Gadeberg P et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology 2002; 58: 31-6.
17. Svensson JO, Barkholt L, Säwe J. Determination of acyclovir and its metabolite 9-carboxymethoxymethylguanine in serum and urine using solid-phase extraction and high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 690: 363-6.
18. Cockcroff DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
19. Strazielle N, Ghersi-Egea JF. Factors affecting delivery of antiviral drugs to the brain. Rev Med Virol 2005; 15: 105-33.